Regulation of Cell Growth by Redox-mediated Extracellular Proteolysis of Platelet-derived Growth Factor Receptor β*
- Hiroaki Okuyama‡,
- Yasuyuki Shimahara,
- Norifumi Kawada§,
- Shuichi Seki§,
- Dan Bach Kristensen¶,
- Katsutoshi Yoshizato¶,‖,**,
- Naoki Uyama and
- Yoshio Yamaoka
- From the Department of Gastroenterological Surgery, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto 606-8397, Japan, the §Department of Hepatology, Graduate School of Medicine, Osaka City University, Abeno-ku, Osaka 545-8585, Japan, ¶Hiroshima Proteome Laboratory, Regional Science Promoter Program, Japan Science and Technology Corporation (JST), Kagamiyama, Higashi-hiroshima, Hiroshima 739-0046, ‖Hiroshima Tissue Regeneration Project, Hiroshima Prefecture Collaboration of Regional Entities for the Advancement of Technological Excellence, JST, Kagamiyama, Higashi-hiroshima, Hiroshima 739-0046, and **Department of Biological Science, Graduate School of Science, Hiroshima University, Kagamiyama, Higashi-hiroshima, Hiroshima 739-8526, Japan
Abstract
Redox-regulated processes are important elements in various cellular functions. Reducing agents, such asN-acetyl-l-cysteine (NAC), are known to regulate signal transduction and cell growth through their radical scavenging action. However, recent studies have shown that reactive oxygen species are not always involved in ligand-stimulated intracellular signaling. Here, we report a novel mechanism by which NAC blocks platelet-derived growth factor (PDGF)-induced signaling pathways in hepatic stellate cells, a fibrogenic player in the liver. Unlike in vascular smooth muscle cells, we found that reducing agents, including NAC, triggered extracellular proteolysis of PDGF receptor-β, leading to desensitization of hepatic stellate cells toward PDGF-BB. This effect was mediated by secreted mature cathepsin B. In addition, type II transforming growth factor-β receptor was also down-regulated. Furthermore, these events seemed to cause a dramatic improvement of rat liver fibrosis. These results indicated that redox processes impact the cell's response to growth factors by regulating the turnover of growth factor receptors and that “redox therapy” is promising for fibrosis-related disease.
- VSMC
- vascular smooth muscle cell(s)
- NAC
- N-acetyl-l-cysteine
- PDGF
- platelet-derived growth factor
- PDGFR
- platelet-derived growth factor receptor
- HSC
- hepatic stellate cell
- BSO
- l-buthionine-(S,R)-sulfoximine
- E64
- l-3-carboxy-2,3-trans-epoxypropionyl-(4-guanidine)butane
- E64-c
- N-[N-(l-3-trans-carboxirane-2-carbonyl)-l-leucyl]-3-methylbutylamine
- E64-d
- ethyl-(2S,3S)-3-[(S)-3-methyl-1-(3-methylbutylcarbamoyl)-butylcarbamoyl]-2-oxiranecarboxylate
- CA074
- N-(l-3-trans-prorylcarbamoyloxirane-2-carbonyl)-l-isoleucyl-l-proline
- 2-ME
- 2-mercaptoethanol
- TGF
- transforming growth factor
- TGF-βR
- transforming growth factor-β receptor
- α-SMA
- smooth muscle α-actin
- TAA
- thioacetamide
- IP
- immunoprecipitation
- WB
- Western blot
- MAP
- mitogen-activated protein
- PSI
- carbobenzoxy-l-isoleucyl-γ-t-butyl-l-glutamyl-l-alamyl-l-leucinal
- MG115
- carbobenzoxy-l-leucyl-l-leucyl-l-norvalinal
- Received April 5, 2001.
- The American Society for Biochemistry and Molecular Biology, Inc.











